Metastatic Hormone-sensitive Prostate Cancer research hub

A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide

This study looks at real-world results for men with prostate cancer that has spread and is sensitive to hormones. It compares two medicines, apalutamide and enzalutamide, which are given alongside standard hormone therapy to see how well they work.

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

This study looks at a new injection, ASP5541, for advanced prostate cancer that has spread. It compares ASP5541 to a standard tablet treatment, abiraterone acetate, to see how safe and effective it is.

A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice

This study looks at how men with advanced prostate cancer respond to darolutamide and hormone therapy, sometimes with chemotherapy, in real-world settings. It aims to understand treatment effectiveness, safety, and patient experiences to help improve care.

Studying Treatments in patients receiving androgen deprivation therapy (ADT) for Metastatic Prostate Cancer: Evaluation of Drug and radiation Efficacy: A 2nd multi-arm multi-stage randomised controlled trial (STAMPEDE2)

This study, called STAMPEDE2, is looking at new treatments for men with prostate cancer that has spread. It compares different treatments, including a drug called Pluvicto, to see if they help men live longer and have a better quality of life.

Phase III Randomized, International, Open-Label Clinical Trial of Treatment Intensification with Docetaxel plus Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment with Apalutamide: REINFORCE Trial

This study looks at a new way to treat prostate cancer that has spread. It combines existing treatments to see if it can keep the cancer from getting worse for longer. It focuses on men whose cancer didn't respond enough to the first treatment.

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)